Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 16, 2014Alimentary Pharmacology & TherapeuticsOpen Access

Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAnna AlisiBambino Gesù Children's HospitalGBGiorgio BedogniOspedale "Santa Maria delle Croci" di RavennaGBGiuseppe BavieraASL Roma

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Alisi et al. (2014) studied this question.

synapsesocial.com/papers/6a0986d916dfdfe7ed342a4dhttps://doi.org/10.1111/apt.12758
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASH2012 · 1,731 citations
  2. 2Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease2013 · 49 citations
  3. 3The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity2013 · 179 citations
  4. 4GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease2012 · 88 citations
  5. 5VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice†2008 · 265 citations